Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
481 to 500 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA093606 | Regulation of EBV Latency by EBNA1 | 1 | 2022 |
| R01CA149385 | Mechanisms of gene amplification in human cancers | 1 | 2022 |
| R01CA151354 | Biological Validation of Candidate Myeloma Driver Genes | 1 | 2022 |
| R01CA167291 | Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations | 1 | 2022 |
| R01CA201446 | Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway | 1 | 2022 |
| R01CA211098 | Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease | 1 | 2022 |
| R01CA214880 | Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance | 1 | 2022 |
| R01CA215151 | Impact of germline variants on racial and ethnic differences in somatic mutation frequency | 1 | 2022 |
| R01CA223388 | MOLECULAR DISSECTION OF SEIZURE MICROENVIRONMENT IN MALIGNANT GLIOMA | 1 | 2022 |
| R01CA227136 | Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems | 1 | 2022 |
| R01CA227934 | Understanding DNA break repair pathway choice regulation by the cNHEJ inhibitor CYREN | 1 | 2022 |
| R01CA229803 | Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer | 1 | 2022 |
| R01CA231141 | Genetics of Graft-versus-Host Disease | 1 | 2022 |
| R01CA231267 | (PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN) | 1 | 2022 |
| R01DK115398 | Integrated high-throughput functional assays to identify ulcerative colitis causal risk variants | 1 | 2022 |
| R01DK120292 | Obesity-induced mesenchymal stem cell senescence | 1 | 2022 |
| R01GM108583 | Investigation of DNA Modifying Enzymes by Computational Simulations: Development and Applications | 1 | 2022 |
| R01GM132263 | Molecular mechanisms of DNA mismatch repair initiation | 1 | 2022 |
| R01GM134426 | Theoretical Models of Single Molecule Dynamics from Minimal Photon Numbers | 1 | 2022 |
| R01HL104608 | New Approaches for Empowering Studies of Asthma in Populations of African Descent | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=25